Minodronic acid

Base Information

• Chemical Name: Minodronic acid
• CAS No.: 180064-38-4
• Deprecated CAS: 127657-42-5
• Molecular Formula: C9H12N2O7P2
• Molecular Weight: 322.15
• Hs Code.: 2933990090
• European Community (EC) Number: 696-656-6
• NSC Number: 725590
• UNII: 40SGR63TGL
• DSSTox Substance ID: DTXSID4048779
• Nikkaji Number: J576.139E
• Wikipedia: Minodronic_acid
• Wikidata: Q2823280
• NCI Thesaurus Code: C81673
• Pharos Ligand ID: BG4V8RFPL91T
• Metabolomics Workbench ID: 149829
• ChEMBL ID: CHEMBL319144
• Mol file: 180064-38-4.mol

Synonyms:(1-hydroxy-2-(imidazo(1,2-a)-pyridin-3-yl)ethylidene)bisphosphonic acid monohydrate;1-hydroxy-2-(imidazo(1,2-a)pyridin-3-yl)ethane-1,1-bisphosphonic acid monohydrate;minodronate;minodronic acid hydrate;ONO-5920;Phosphonic acid, (1-hydroxy-2-imidazo(1,2-a)pyridin-3-ylethylidene)bis-;YH 529;YH-529;YH529;YM 529;YM-529;YM529

Chemical Property of Minodronic acid

Chemical Property:

• Refractive Index: 1.744
• PKA: 1.48±0.10(Predicted)
• PSA: 172.21000
• Density: 1.973 g/cm³
• LogP: -0.12170
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• XLogP3: -2.2
• Hydrogen Bond Donor Count: 5
• Hydrogen Bond Acceptor Count: 8
• Rotatable Bond Count: 4
• Exact Mass: 322.01197472
• Heavy Atom Count: 20
• Complexity: 439

Purity/Quality:

99% ^*data from raw suppliers

MinodronicAcid ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: C1=CC2=NC=C(N2C=C1)CC(O)(P(=O)(O)O)P(=O)(O)O
• Recent ClinicalTrials: Efficacy and Safety of Minodronate in Patients With Low Back Pain
• Recent NIPH Clinical Trials: Dose minodronic acid for patients of differentiated thyroid carcinoma with TSH suppressive therapy after total-thyroidectomy prevent osteoporosis?
• Description: Minodronic acid hydrate, a third-generation bisphosphonate, was approved and launched in Japan for the oral treatment of osteoporosis. Osteoporosis is a skeletal disorder characterized by low bone mass and structural deterioration of bone tissue resulting in bone fragility and increased susceptibility to fractures, particularly of the hip, spine, and wrist. It is the most common type of metabolic bone disease and a major health concern affecting 200 million women worldwide. Minodronic acid is the newest nitrogen-containing bisphosphonate to reach the market. In vitro, it inhibits recombinant human FPP synthase activity with similar potency as zoledronic acid (IC50 = 3 nM for both agents). The most common adverse events associated with minodronic acid included stomach and abdominal discomfort, abdominal pain, decrease in blood calcium level, and gastritis. The chemical synthesis of minodronic acid starts with a condensation reaction of 2-aminopyridine with ethyl 4-bromo-3-oxobutyrate by means of sodium bicarbonate to produce 2-(imidazo[1,2-a]pyridin-3-yl)acetic acid ethyl ester, which is hydrolyzed to the corresponding carboxylic acid with potassium hydroxide. Treatment of the carboxylic acid intermediate with phosphorus acid and phosphorus trichloride followed by hydrolysis with hydrochloric acid gives minodronic acid.
• Uses: Minodronic acid is developed for osteoporosis treatment.